Literature DB >> 11095773

Immune Reconstitution and the Consequences for Opportunistic Infection Treatment and Prevention.

.   

Abstract

Effective antiretroviral therapy that suppresses HIV replication is associated with dramatic increases in CD4 counts. Recent evidence suggests that this CD4 cell increase is biphasic in nature, with an initial phase (in the first 2 to 3 months) that represents redistribution of lymphocytes into the periphery and a second phase that is associated with true immunologic recovery and reconstitution. Immunologically there is evidence of increase in naive T cells, recovery of in vitro responses to microbial antigens, and repair of the damaged diversity of T cells. Clinically, this immune recovery has been characterized by decreasing morbidity and mortality from opportunistic infections, an ability to treat previously intractable infections, immune-mediated syndromes, and increasing reports of the ability to discontinue primary and secondary prophylaxis. Although there are still unresolved questions about the completeness of the immune recovery, most available evidence suggests in most patients the degree of immune reconstitution with effective antiretroviral therapy is sufficient to be protective against most opportunistic infections, and ultimately additional antimicrobial prophylaxis will be unnecessary.

Entities:  

Year:  1999        PMID: 11095773     DOI: 10.1007/s11908-999-0016-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  39 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

2.  Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

Authors:  M Narita; D Ashkin; E S Hollender; A E Pitchenik
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

3.  Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy.

Authors:  H Valdez; B M Gripshover; R A Salata; M M Lederman
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

4.  1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-06-27

5.  Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.

Authors:  M A Jacobson; M Zegans; P R Pavan; J J O'Donnell; F Sattler; N Rao; S Owens; R Pollard
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

6.  Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.

Authors:  D W Notermans; S Jurriaans; F de Wolf; N A Foudraine; J J de Jong; W Cavert; C M Schuwirth; R H Kauffmann; P L Meenhorst; H McDade; C Goodwin; J M Leonard; J Goudsmit; S A Danner
Journal:  AIDS       Date:  1998-01-22       Impact factor: 4.177

7.  Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

Authors:  C Tural; J Romeu; G Sirera; D Andreu; M Conejero; S Ruiz; A Jou; A Bonjoch; L Ruiz; A Arnó; B Clotet
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

8.  Opportunistic infections occurring during highly active antiretroviral treatment.

Authors:  C Michelet; C Arvieux; C François; J M Besnier; J P Rogez; J P Breux; F Souala; C Allavena; F Raffi; M Garre; F Cartier
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

9.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

Review 10.  Report of the NIH Panel To Define Principles of Therapy of HIV Infection.

Authors: 
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.